In this issue:
Histopathic regression in patients with cutaneous melanoma
Clinical impact of PPIs on melanoma patients
Antibiotic treatment and survival outcomes in treatment naïve patients
Population-based validation of the MIA and MSKCC tools
Pembrolizumab versus placebo as adjuvant therapy
The effect of surgical timing in nonmetastatic melanoma
Individualised mRNA-4157 (V940) plus pembrolizumab vs monotherapy
Smoking status and survival in early-stage primary cutaneous melanoma
Health economic consequences due to COVID-19–related delay in melanoma diagnosis
Real-world HRQOL outcomes with adjuvant anti-PD1 therapy
Please login below to download this issue (PDF)